Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives.

ABSTRACT: Consolidative radiation therapy for early-stage Hodgkin lymphoma (HL) improves progression-free survival. Unfortunately, first-generation techniques, relying on large irradiation fields, were associated with an increased risk of secondary cancers, and of cardiac and lung toxicity. Fortunately, the use of smaller target volumes combined with technological advances in treatment techniques currently allows efficient organs-at-risk sparing without altering tumoral control. Recently, proton therapy has been evaluated for mediastinal HL treatment due to its potential to significantly reduce the dose to organs-at-risk, such as cardiac substructures. This is expected to limit late radiation-induced toxicity and possibly, second-neoplasm risk, compared with last-generation intensity-modulated radia

SUBMITTER: Loap P 

PROVIDER: S-EPMC8345082 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature